Einstein-Rockefeller-CUNY Center for AIDS Research

Biomarkers & Advanced Technology Core

To support the overarching goal of the ERC-CFAR to end the HIV epidemic, the Biomarker and Advanced Technology Core (BATC) will provide state-of-the-art and innovative technologies, services and consultations to accelerate the development of novel approaches for prevention and cure including vaginal rings for sustained ART release (prevention), broadly neutralizing antibodies (bNAb) (prevention and cure), potent immunoactivators such as IL-15 superagonists (prevention and cure), and vaccines (prevention). The BATC will also support implementation research to improve the effectiveness of pre-exposure prophylaxis (PrEP), PEP (post-exposure prophylaxis) and treatment as prevention (TasP). The BATC infrastructure was developed specifically in response to the identified and articulated needs of established HIV/AIDS researchers and new investigators who are expanding their research programs to include HIV/AIDS-related studies at Einstein, Rockefeller, and CUNY. The BATC is also highly responsive to providing technical support to enable investigators to accomplish the current and emerging goals of the two Scientific Working Groups (SWGs), the HIV Eradication SWG and the Patient and Population Health Outcomes Research (PPHOR) SWG.

  • To provide investigators with the infrastructure and optimized technologies and protocols to support their HIV prevention studies.
  • To provide investigators with technological support to investigate and evaluate novel approaches to achieve a functional cure for HIV.
  • To provide a centralized resource for supporting HIV pathogenesis studies.
  • To provide access to deep HIV sequencing and mutational analysis for drug-resistance, immune escape and co-receptor tropism in laboratory and clinical isolates through the Case Western CFAR (http://casemed.case.edu/cfar/cores/virology)
  • To transfer new technologies from individual ERC-CFAR research labs or from labs at other institutions into the BATC to make them broadly available to ERC-CFAR members.
  • To train ERC-CFAR investigators in molecular and cellular techniques for HIV research.
  • For further information or to access the Biomarker and Advanced Technologies Core services, please contact Drs. Berman or Almo. 

Dr. Joan Berman
Director, Biomarkers & Advanced Technology Core
Professor, Pathology and of Microbiology & Immunology, Einstein 

Dr. Steven Almo
Co-Director, Biomarkers & Advanced Technology Core
Chair and Professor, Biochemistry and Physiology & Biophysics
Wollowick Family Foundation Chair, Multiple Sclerosis and Immunology, Einstein
Director, Macromolecular Therapeutics Developmental Facility


Dr. Eduardo Butelman
Associate Director, Biomarkers & Advanced Technology Core
Research Associate Professor, Rockefeller  


Einstein Logo 

Rockefeller Logo 

CUNY Logo 


ERC-CFAR at a Glance

Partner Institutions 

  • Albert Einstein College of Medicine
  • Rockefeller University
  • The City University of New York (CUNY)


Total ERC-CFAR members

  • 183 Full members
  • 10 Affiliate members

CFAR member trainees funded by NIH K awards

  • 15 Full members

NIH Funding 

FY2015 OAR NIH AIDS FRB grants

$34,084,840 Total costs


New NIH AIDS grants awarded in FY2016

$7,345,645 Total annual costs


FY2014 non-AIDS NIH grants

$34,745,334 Total costs

Publications (first 6 months of 2016) 

Total Publications: 240

Publications multi-authored
by ERC-CFAR members: 91



Director: Dr. H. Goldstein



Directors: Dr. V. Prasad & Dr. C. Cunningham


Biomarkers & Advanced Technologies 

Directors: Dr. J. Berman & Dr. S. Almo


Behavioral Science 

Director: Dr. L. Bauman


Clinical Translational Implementation Science 

Director: Dr. K. Anastos


Scientific Working Groups 

HIV and Eradication 

Directors: Dr. G. Kalpana & Dr. M. Caskey


Patient and Population Health Outcomes Research 

Directors: Dr. D. Nash & Dr. J. Arnsten  

New 2016 NIH Grants Awards 

Click here to log in

In the Media

Can an Immune Strategy Used to Treat Cancer Also Wipe Out HIV Infections?

Harris Goldstein, M.D., describes his new research, in Science Translational Medicine, that uses genetically reprogrammed T cells to successfully fight HIV infection in mice. Dr. Goldstein is professor of pediatrics and of microbiology & immunology and director of the Einstein-Rockefeller-CUNY Center for AIDS Research.

(Thursday, Aug 08, 2019)

Trump's HIV Plan Met With Both Cautious Optimism, Flat-Out Skepticism

Harris Goldstein, M.D., says he is encouraged by the prospect of increased federal funds for regional AIDS research centers that help advance treatments and improve health outcomes. Dr. Goldstein is director of the Einstein-Rockefeller-CUNY Center for AIDS Research and an attending physician at Children’s Hospital at Montefiore.

(Tuesday, Feb 12, 2019)

coverage on other stories